International Journal of Cancer Management

Published by: Kowsar

Evaluation of the Celecoxib Effect against Radiotherapy Induced Acute Toxicities in the Patients with Prostate Cancer Compared with Placebo Group

Saeedeh Mir Mohammadi Rad 1 , Mohsen Bakhshandeh 2 , * , Mahmoud Reza Aghamiri 3 , Marzieh Rohani-Rassf 4 , Mona Malekzadeh Moghani 5 , Alireza Khoshghadam 6 and Ehsan Akbari Hamed 7
Authors Information
1 Department of Radiology, Faculty of paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Radiology Technology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Division of Radiation Medicine, Shahid Beheshti University, Tehran, IR Iran
4 Department of Epidemiology, School of Public Health, Shahid Beheshti University Medical Sciences, Tehran, IR Iran
5 Department of Radiotherapy, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
6 Department of Physics, Mahdieh Diagnostic and Medical Center, Hamedan, IR Iran
7 Department of Radiotherapy, Mahdieh Diagnostic and Medical Center, Hamedan, IR Iran
Article information
  • International Journal of Cancer Management: December 2017, 10 (12); e9484
  • Published Online: December 31, 2017
  • Article Type: Research Article
  • Received: October 26, 2016
  • Revised: September 9, 2017
  • Accepted: December 20, 2017
  • DOI: 10.5812/ijcm.9484

To Cite: Mir Mohammadi Rad S, Bakhshandeh M, Aghamiri M R, Rohani-Rassf M, Malekzadeh Moghani M, et al. Evaluation of the Celecoxib Effect against Radiotherapy Induced Acute Toxicities in the Patients with Prostate Cancer Compared with Placebo Group, Int J Cancer Manag. 2017 ; 10(12):e9484. doi: 10.5812/ijcm.9484.

Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107. [PubMed: 21296855].
  • 2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi: 10.3322/caac.20073. [PubMed: 20610543].
  • 3. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43(4):316-81. [PubMed: 15303499].
  • 4. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48(3):635-42. [PubMed: 11020558].
  • 5. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58(4):196-213. doi: 10.3322/CA.2008.0002. [PubMed: 18502900].
  • 6. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353(9149):307-14. [PubMed: 9929039].
  • 7. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol. 2006;59(1):51-64. doi: 10.1016/j.critrevonc.2006.01.003. [PubMed: 16531064].
  • 8. Chen CC, Sun YT, Chen JJ, Chang YJ. Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol. 2001;59(3):493-500. [PubMed: 11179444].
  • 9. Sooriakumaran P, Langley SE, Laing RW, Coley HM. COX-2 inhibition: a possible role in the management of prostate cancer?. J Chemother. 2007;19(1):21-32. doi: 10.1179/joc.2007.19.1.21. [PubMed: 17309847].
  • 10. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000;6(1):135-8. [PubMed: 10656441].
  • 11. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7(11):1163-70. [PubMed: 11032965].
  • 12. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946-52. doi: 10.1056/NEJM200006293422603. [PubMed: 10874062].
  • 13. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 2001;29(1):23-8. [PubMed: 11310211].
  • 14. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42(1):73-8. [PubMed: 10579801].
  • 15. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 2000;86(6):736-41. [PubMed: 11069387].
  • 16. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891-9. doi: 10.1056/NEJMoa021735. [PubMed: 12621133].
  • 17. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep. 2001;8(3):655-7. [PubMed: 11295097].
  • 18. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5(2):138-46. [PubMed: 8172988].
  • 19. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609-14. doi: 10.1056/NEJM199509073331001. [PubMed: 7637720].
  • 20. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996;7(2):203-5. [PubMed: 8834563].
  • 21. McGettigan P, Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des. 2000;6(17):1693-724. [PubMed: 11102559].
  • 22. Fort J. Celecoxib, a COX-2--specific inhibitor: the clinical data. Am J Orthop (Belle Mead NJ). 1999;28(3 Suppl):13-8. [PubMed: 10193998].
  • 23. Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med. 2001;110 Suppl 3A:13S-9S. [PubMed: 11173045].
  • 24. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95(7):1681-90. doi: 10.1111/j.1572-0241.2000.02194.x. [PubMed: 10925968].
  • 25. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000;60(5):1326-31. [PubMed: 10728694].
  • 26. Kamijo T, Sato T, Nagatomi Y, Kitamura T. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol. 2001;8(7):S35-9. [PubMed: 11442675].
  • 27. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164(3 Pt 1):820-5. [PubMed: 10953162].
  • 28. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275(15):11397-403. [PubMed: 10753955].
  • 29. Srinath P, Rao PN, Knaus EE, Suresh MR. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 2003;23(5A):3923-8. [PubMed: 14666698].
  • 30. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475-81. doi: 10.1016/S0140-6736(05)17864-7. [PubMed: 15705456].
  • 31. Sooriakumaran P. COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad Med J. 2006;82(966):242-5. doi: 10.1136/pgmj.2005.042234. [PubMed: 16597810].
  • 32. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13-47. [PubMed: 10758303].
  • 33. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010;16(5):1384-90. doi: 10.1158/1078-0432.CCR-09-0788. [PubMed: 20179228].
  • 34. Castelao JE, Bart R3, DiPerna CA, Sievers EM, Bremner RM. Lung cancer and cyclooxygenase-2. Ann Thorac Surg. 2003;76(4):1327-35. [PubMed: 14530048].
  • 35. Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res. 2009;29(5):1483-8. [PubMed: 19443354].
  • 36. Mehar A, Macanas-Pirard P, Mizokami A, Takahashi Y, Kass GE, Coley HM. The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J Pharmacol Exp Ther. 2008;324(3):1181-7. doi: 10.1124/jpet.107.131383. [PubMed: 18089846].
  • 37. Sooriakumaran P, Macanas-Pirard P, Bucca G, Henderson A, Langley SE, Laing RW, et al. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. Cancer Genomics Proteomics. 2009;6(2):93-9. [PubMed: 19451093].
  • 38. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res. 2004;2(11):632-42. [PubMed: 15561779].
  • 39. Anai S, Tanaka M, Shiverick KT, Kim W, Takada S, Boehlein S, et al. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. J Urol. 2007;177(5):1913-7. doi: 10.1016/j.juro.2007.01.019. [PubMed: 17437847].
  • 40. Jun HJ, Kim YM, Park SY, Park JS, Lee EJ, Choi SA, et al. Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib. Int J Radiat Oncol Biol Phys. 2009;75(1):225-34. doi: 10.1016/j.ijrobp.2009.04.086. [PubMed: 19695440].
  • 41. Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res. 2005;65(20):9501-9. doi: 10.1158/0008-5472.CAN-05-0220. [PubMed: 16230415].
  • 42. Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ, et al. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis. 2003;24(4):665-71. [PubMed: 12727794].
  • 43. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90(1-3):179-85. doi: 10.1016/j.schres.2006.11.016. [PubMed: 17208413].
  • 44. Funakoshi-Tago M, Shimizu T, Tago K, Nakamura M, Itoh H, Sonoda Y, et al. Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol. 2008;76(5):662-71. doi: 10.1016/j.bcp.2008.06.015. [PubMed: 18644347].
  • 45. Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, et al. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res. 2007;13(3):965-71. doi: 10.1158/1078-0432.CCR-06-0551. [PubMed: 17289892].
  • 46. Razzaghdoust A, Mozdarani H, Mofid B. Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial. Strahlenther Onkol. 2014;190(8):739-44. doi: 10.1007/s00066-014-0602-8. [PubMed: 24619016].
  • 47. Dunst J, Semlin S, Pigorsch S, Muller AC, Reese T. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol. 2000;176(9):416-21. [PubMed: 11050915].
  • 48. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000;18(11):2226-33. doi: 10.1200/JCO.2000.18.11.2226. [PubMed: 10829042].
  • 49. Hejazi J, Rastmanesh R, Taleban FA, Molana SH, Hejazi E, Ehtejab G, et al. Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study. Nutr Cancer. 2016;68(1):77-85. doi: 10.1080/01635581.2016.1115527. [PubMed: 26771294].
  • 50. Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol. 2006;1:9. doi: 10.1186/1748-717X-1-9. [PubMed: 16722607].
  • 51. Kao J, Genden EM, Chen CT, Rivera M, Tong CC, Misiukiewicz K, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer. 2011;117(14):3173-81. doi: 10.1002/cncr.25786. [PubMed: 21246519].
  • 52. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res. 2006;12(7 Pt 1):2172-7. doi: 10.1158/1078-0432.CCR-05-2067. [PubMed: 16609031].
  • 53. Gaffney DK, Winter K, Dicker A, Miller B, Jhingran A, Ryu J, et al. A Phase I–II Study of COX-2 Inhibitor, Celebrex (Celecoxib) and Chemoradiation in Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG 0128. Int J Radiat Oncol Biol Phys. 2005;63:S93-4. doi: 10.1016/j.ijrobp.2005.07.161.
  • 54. Crane CH, Mason K, Janjan NA, Milas L. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol. 2003;26(4):S81-4. [PubMed: 12902862].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments